乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ASCO

<乌鸦传媒>'Practice Changing' Trial for Inoperable Locally Advanced NSCLC

EGFR testing now needed for all patients with stage III disease, experts say

<乌鸦传媒>Intralesional Therapy for Melanoma Effective, May Have Systemic Activity

Preoperative antibody fusion daromun significantly reduced relapse versus upfront surgery

<乌鸦传媒>Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma

Second belantamab mafodotin-containing triplet to show potency in this setting

<乌鸦传媒>Virtual and In-Person Palliative Care Equally Beneficial in Advanced Lung Cancer

No differences observed in quality of life metric, patient and caregiver satisfaction

<乌鸦传媒>No Survival Advantage With Sacituzumab Over Chemo in Previously Treated NSCLC

Results are "disappointing as we need better therapies in the refractory space," expert says

<乌鸦传媒>Subcutaneous Amivantamab Plus Lazertinib Non-Inferior to IV Dosing in NSCLC

Unexpectedly offers a possible overall survival benefit, researchers say

<乌鸦传媒>Novel Bispecific in EGFR-Mutant Lung Cancer Boosts PFS After Targeted Agents

China-based trial may present a hurdle to FDA approval, however

<乌鸦传媒>Kinder, Gentler Regimen for Classical Hodgkin Prevails in Randomized Trial

Better efficacy with brentuximab vedotin versus standard chemo, substantially less toxicity

<乌鸦传媒>STAMP Inhibitor Tops Imatinib, Second-Gen TKIs for Newly Diagnosed CML

The benefit-risk profile could change the treatment paradigm in CML, expert says

<乌鸦传媒>Unprecedented PFS Results in ALK-Positive Lung Cancer Trial

"We have not seen anything close to this," says expert

<乌鸦传媒>HPV Vaccination Reduces Risk of Multiple Types of Cancer in Men and Women

Large cohort study provides some of the first evidence of cancer reduction after vaccination

<乌鸦传媒>Most Women Can Have Successful Pregnancies After Breast Cancer Treatment

Fertility preservation before treatment strongly predictive of live births, study shows

<乌鸦传媒>Estrogen-Only Therapy for Menopausal Symptoms Increases Ovarian Cancer Risk

Incidence, mortality double over 20 years, while estrogen plus MPA lowers endometrial cancer risk

<乌鸦传媒>TTFields Therapy Yields OS Improvement in Second-Line NSCLC

However, device was not tested alongside current standard of care, expert points out

<乌鸦传媒>Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer

No PFS, OS benefit with first-line versus second-line CDK4/6 inhibition, more toxicity, cost

<乌鸦传媒>Skipping Radiotherapy 'Seems Safe' for PMBCL Patients in Remission

PET-negative patients after chemoimmunotherapy fared well with observation alone

<乌鸦传媒>FGFR Inhibitor Stakes Claim to Post-Anti-PD-1 Role in Advanced Bladder Cancer

Survival benefit supports FGFR testing for all patients with metastatic disease, researcher says

<乌鸦传媒>Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLC

"Immediate changes" needed to patient care to avoid unnecessary toxicity, says ASCO expert

<乌鸦传媒>Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Years

Retrospective study finds no difference in OS between patients who stop and those who continue

<乌鸦传媒>No Survival Benefit With Immune Checkpoint Inhibitor Rechallenge in Metastatic RCC

The strategy also led to increased toxicity

<乌鸦传媒>New Data in NSCLC Bolster Support for Perioperative Immunotherapy

EFS benefit with pembrolizumab in KEYNOTE-671, but no OS benefit "yet," says investigator

<乌鸦传媒>Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma

The CAR T-cell therapy led to significantly longer overall survival

<乌鸦传媒>New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials

High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents

<乌鸦传媒>CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myeloma

Ciltacabtagene autoleucel improved progression-free survival versus two standard triplets

<乌鸦传媒>T-DXd Proves Mettle in Multiple Solid Tumors

Data from ongoing DPT02 trial show broad activity in HER2-expressing advanced disease

<乌鸦传媒>Omitting RT Safe in Many Locally Advanced Rectal Cancers

Most intermediate-risk cases can be cured without pelvic radiation, says investigator

<乌鸦传媒>Novel IDH1/2 Inhibitor Shows 'Dramatic Effect' in Low-Grade Glioma

INDIGO data demonstrate that some patients can delay "toxic" chemo and radiation, says expert

<乌鸦传媒>Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphoma

SWOG trial had goal of "harmonizing" treatment in adults, children with advanced-stage disease

<乌鸦传媒>New Standard in Operable EGFR-Positive Lung Cancer

"We should firmly close the door on one-size-fits-all treatment," says ASCO expert

<乌鸦传媒>New Ovarian Cancer Drug Extends Survival in Resistant Disease

"Practice changing" findings for tough-to-treat patient population

<乌鸦传媒>Neoadjuvant Chemo Flops Versus Upfront Surgery for Resectable Pancreatic Cancer

Survival 13 months better with surgery, but "curiosities" in neoadjuvant arm muddy the results

<乌鸦传媒>Novel Anti-HER2 Drugs 'Impressive' in Advanced Biliary Cancer

Response rates reached 41-47% with different approaches in rare disease

<乌鸦传媒>Chemo-Free Approach Works in Subset of Patients With HER2+ Early Breast Cancer

Impressive 3-year invasive DFS seen with adaptive response strategy using FDG-PET

<乌鸦传媒>Pricey Drug Combo Boosts PFS in First-Line Advanced Ovarian Cancer

Questions about anti-PD-L1 contribution, cost, and access to durvalumab, bevacizumab, olaparib

<乌鸦传媒>De-Escalated Surgery Suffices for Low-Risk Cervical Cancer

Simple hysterectomy non-inferior to radical operation

<乌鸦传媒>CDK4/6 Extends Reach Into Early-Stage Breast Cancer

Addition of ribociclib to endocrine therapy boosts disease-free survival in high-risk disease

<乌鸦传媒>Medicaid Expansion Tied to Better Outcomes in Black Patients With GI Cancers

Two-year mortality decreased for three types of GI cancer in expansion vs non-expansion states

<乌鸦传媒>Less-Invasive Surgery for Pancreatic Cancer Proves Safe, Effective

Radical resection rate noninferior to open surgery in early-stage disease, with similar survival

<乌鸦传媒>Monoclonal Antibody Reduced Need For Transfusions in Low-Risk MDS

Results suggest a "paradigm shift" in the treatment of anemia for these patients

<乌鸦传媒>Cross-Border Collaboration Improves Survival in Pediatric Leukemia Patients

5-year OS increased to 100% in standard-risk ALL patients at a Tijuana hospital

1